InsidersTradesSigma
Follow the Surgery Partners, Inc. share price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Surgery Partners, Inc. has published 216 insider filings. Market capitalisation: €1.8bn. The latest transaction was disclosed on 20 August 2026 (Acquisition). Among the most active insiders: Evans Jason Eric. All data is free.
216
Insider Decl.
n/a
Thresholds
€1m
5 ops.
Buy Volume
€988m
128 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Surgery Partners, Inc. Buy (bullish), based on 11 analysts. Average price target: US$18.73.
47Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 20,062 of 29,063 companies
39.1
score / 100
Value54
Quality24
FCF yld11%
Earn yld-4.3%
EV/EBITDA10.3x
ROE2.3%
Gross mgn23%
Net mgn-2.4%
Debt/EBITDA7.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 20 August 2026
Declarations216 total
11,250 shares@ US$14.330.0087% mcap5.8% of flowCommon StockSEC:0001638833-26-000081:0
Canonical exit: 16 Nov 2026 (T+90)
10,000 shares@ US$14.350.0078% mcap5.5% of flowCommon StockSEC:0001638833-26-000079:0
Canonical exit: 16 Nov 2026 (T+90)
34,364 shares@ US$14.550.024% mcap0.1% of flowCommon StockSEC:0001638833-26-000066:0
11,670 shares@ US$13.710.0076% mcap0.0% of flowCommon StockSEC:0001638833-26-000064:0
11,670 shares@ US$13.710.0076% mcap23.6% of flowCommon StockSEC:0001638833-26-000060:0
11,670 shares@ US$13.710.0076% mcap100.0% of flowCommon StockSEC:0001638833-26-000059:0
11,670 shares@ US$13.710.0076% mcap100.0% of flowCommon StockSEC:0001638833-26-000061:0
11,670 shares@ US$13.710.0076% mcap6.6% of flowCommon StockSEC:0001638833-26-000058:0
11,670 shares@ US$13.710.0076% mcap23.6% of flowCommon StockSEC:0001638833-26-000062:0
3,469 shares@ US$12.837.3% of flowCommon StockSEC:0001638833-26-000034:0
3,657 shares@ US$12.542.5% of flowCommon StockSEC:0001638833-26-000033:0
8,867 shares@ US$12.501.9% of flowCommon StockSEC:0001638833-26-000032:0
20,400 shares@ US$12.471.7% of flowCommon StockSEC:0001638833-26-000031:0
5,798 shares@ US$13.171.2% of flowCommon StockSEC:0001638833-26-000030:0
42,523 shares@ US$14.118.5% of flowCommon StockSEC:0001638833-26-000022:0
8,785 shares@ US$13.706.2% of flowCommon StockSEC:0001638833-26-000019:0
42,523 shares@ US$14.1132.5% of flowCommon StockSEC:0001638833-26-000018:0
11,462 shares@ US$13.791.1% of flowCommon StockSEC:0001638833-26-000024:0
14,574 shares@ US$13.843.4% of flowCommon StockSEC:0001638833-26-000023:0
7,736 shares@ US$13.6014.7% of flowCommon StockSEC:0001638833-26-000021:0
272 shares@ US$13.930.8% of flowCommon StockSEC:0001638833-26-000020:0
77,736 shares@ US$16.0867.5% of flowCommon StockSEC:0002100574-26-000003:0
5,726 shares@ US$22.483.9% of flowCommon StockSEC:0001638833-25-000151:0
00Common StockSEC:0001638833-25-000146:0
20,018 shares@ US$22.7418.3% of flowCommon StockSEC:0001638833-25-000145:0
25 of 216 declarations
关于 Surgery Partners, Inc.
Surgery Partners, Inc. (NASDAQ: SGRY) 是一家总部位于美国田纳西州布伦特伍德的美国医疗服务公司，专注于门诊手术和短期住院手术护理。该公司建立了以医生为中心的运营模式，旨在提供高效、经济的手术护理，同时保持临床质量。Surgery Partners 成立于2004年，通过有机增长和收购相结合的方式进行扩张，已成为美国市场上较大的独立手术服务平台之一。（[ir.surgerypartners.com](https://ir.surgerypartners.com/news-releases/news-release-details/surgery-partners-inc-announces-fourth-quarter-and-full-year-2025?utm_source=openai)） 其资产基础多元化，涵盖门诊手术中心（ASCs）、手术医院、多专业医生诊所和紧急护理设施。这种组合使公司能够接触到患者就医过程中的多个环节，并支持为医生和患者提供更综合的医疗服务模式。Surgery Partners 还强调辅助服务，包括麻醉和多专业临床支持，这有助于其扩大服务范围，并在适当情况下参与更高难度的手术。（[ir.surgerypartners.com](https://ir.surgerypartners.com/news-releases/news-release-details/surgery-partners-inc-announces-fourth-quarter-and-full-year-2025?utm_source=openai)） 从竞争角度来看，Surgery Partners 定位在美国医疗保健领域中一个具有结构性吸引力的细分市场。手术从住院医院向成本较低的门诊环境持续转移仍然是行业的一个关键利好因素，而公司的规模、全国性布局以及在短期住院手术方面的专业化是其市场地位的核心。管理层表示，公司在30个州运营着超过250个地点，这使其拥有显著的地理覆盖范围，同时仍专注于美国市场。这种布局有助于 Surgery Partners 与大型医疗系统和其他独立的 ASC 运营商竞争。（[ir.surgerypartners.com](https://ir.surgerypartners.com/investor-overview?utm_source=openai)） 近期发展值得关注。2026年第一季度，Surgery Partners 报告收入增长 4.5%，并重申了2026年全年指引，预计调整后 EBITDA 至少达到 530 million 美元，收入在 3.35 billion 美元至 3.45 billion 美元之间。2026年3月，公司还宣布了一项股票回购计划。此外，该股票一直是战略重点：2025年1月，Surgery Partners 确认收到贝恩资本（Bain Capital）对其尚未持有的股份发出的非约束性收购要约。这些事件共同突显了公司运营势头和市场对其门诊手术平台的战略兴趣。（[ir.surgerypartners.com](https://ir.surgerypartners.com/news-releases/news-release-details/surgery-partners-inc-announces-first-quarter-2026-results?utm_source=openai)）
